The Novavax NVX-CoV2373 Investigational Vaccine Clinical Study

Novavax’ COVID-19 vaccine candidate, called NVX-CoV2373, is being developed for the prevention of COVID-19 disease. NVX-CoV2373 is made from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. It does not contain any live or inactivated virus, and cannot cause infection or COVID-19 disease.

The study vaccine was created using Novavax’ nanoparticle technology. The vaccine also contains the Company’s patented adjuvant called Matrix-MTM to boost the immune response and stimulate high levels of neutralizing antibodies.

The purpose of the Phase 3 study is to test the safety and efficacy of the vaccine. We want to understand how well the study vaccine works to prevent COVID-19 disease.

The study aims to enroll diverse populations, including those with other underlying health conditions, and in groups hardest hit by COVID-19 who are at high risk of developing severe disease. Visit ClinicalTrials.gov - NCT04611802 for additional details.

Together we can help end uncertainty. Join us.

We need your help to keep learning and improving vaccines against COVID-19. We made history with safe and effective vaccines and we’ll keep working as long as there are people to protect, variants emerging, and research answers needed to end this pandemic. To participate:

  • Fill out the survey again so we have your most current information to match you with a study, even if you filled it out previously!
  • If you haven’t registered to volunteer before, sign up today. There’s still a lot we can do together for those we love.

Volunteer

Content last reviewed on April 14, 2021